IGHE and asthma: In terms of main baseline indicators like the percentage of comorbid asthma, SNOT‐22, or objective characteristics like LMS and serum total IgE, it seems that the disease severity in the ESS trial is no lower than that in the Dupilumab study (shown in Table 2).